Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
39 results about "Erythropoietin receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The erythropoietin receptor (EpoR) is a protein that in humans is encoded by the EPOR gene. EpoR is a 52kDa peptide with a single carbohydrate chain resulting in a n approximately 56-57 kDa protein found on the surface of EPO responding cells. It is a member of the cytokine receptor family. EpoR pre-exists as dimers which upon binding of a 30 kDa ligand erythropoietin (Epo), changes its homodimerized state. These conformational changes result in the autophosphorylation of Jak2 kinases that are pre-associated with the receptor (i.e., EpoR does not possess intrinsic kinase activity and depends on Jak2 activity). At present, the most well-established function of EpoR is to promote proliferation and rescue of erythroid (red blood cell) progenitors from apoptosis.
Erythropoietin receptor antibodies
InactiveUS20050244409A1Increased erythropoiesisAnimal cellsImmunoglobulins against cell receptors/antigens/surface-determinantsErythropoietin receptorMedicine
Erythropoietin receptor agonist and antagonist antibodies and their use in enhancing erythropoiesis are disclosed.
Owner:SMITHKLINE BECKMAN CORP
Aryl and heteroaryl compounds, compositions and methods of use
InactiveUS20050049310A1Reduce hypoxiaInduce red blood cell productionBiocideOrganic chemistryArylErythropoietin receptor
This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. The compounds of Formula (I) may activate an erythropoietin receptor and thus, may be useful to induce red blood cell production. The compounds of Formula (I) and compositions including compounds of Formula (I) may be useful in a variety of applications including the management, treatment and / or control of diseases caused at least in part by deficient (or inefficient) EPO production relative to hemoglobin level.
Owner:VTV THERAPEUTICS LLC
Erythropoietin receptor antibodies
InactiveUS6998124B1Increased erythropoiesisAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsErythropoietin receptorErythropoiesis
Erythropoietin receptor agonist and antagonist antibodies and their use in enhancing erythropoiesis are disclosed.
Owner:SMITHKLINE BECKMAN CORP
Erythropoietin forms with improved properties
InactiveUS7211253B1High activityLong serum half lifeFungiBacteriaErythropoietin receptorDrug biological activity
The invention relates to novel modified erythropoietin (EPO) forms such as fusion proteins comprising a Fc portion of an Ig molecule and a target molecule having the biological activity of EPO. By selective altering of the amino acid sequences of the erythropoietin moiety as well as of the immunoglobulin moiety and the glycosylation pattern of erythropoietin fusion proteins with enhanced biological activity can be obtained. The invention relates also to novel nun-fused EPO molecules which have a pattern of cysteines or disulfide bonding which is distinct from human or animal EPO.
Owner:MERCK PATENT GMBH
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
InactiveUS20120190051A1Eliminate needPeptide/protein ingredientsTransferrinsErythropoietin receptorFactor VIII vWF
Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransfenin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.
Owner:ASTUTE MEDICAL
Drug conjugate comprising an erythropoietin receptor ligand and an anticancer agent
InactiveUS7344699B2Increased toxicityHigh synthetic yieldBiocidePeptide/protein ingredientsErythropoietin receptorAnticarcinogen
Owner:QUEENS UNIV OF BELFAST
Antibodies which activate an erythropoietin receptor
InactiveUS20080182976A1Peptide/protein ingredientsMicroorganism based processesErythropoietin receptorRed blood cell
Owner:AMGEN INC
Purified human erythropoietin receptor protein fragment and antibodies derived therefrom
A E. coli recombinant plasmid expressing a fusion protein having the human erythropoietin receptor extracellular domain is disclosed. A purified fusion protein produced from such a vector is also disclosed, the fusion protein having a cleavage site suitable for separating the erythropoietin receptor extracellular domain from the remainder of the fusion protein. Antibodies having specific binding affinity for a purified extracellular domain polypeptide are also disclosed. The purified human erythropoietin receptor fragment polypeptide binds erythropoietin. The articles, compositions and methods of the invention are useful for studying ligand binding to erythropoietin receptor and for quantitating the amounts of erythropoietin receptor, as well as for understanding receptor structure and signal transduction.
Owner:LEE JONG Y
Polynucleotides and polypeptides of the erythropoietin gene
InactiveUS7041794B2Useful to treat and preventAvoid injuryNervous disorderPeptide/protein ingredientsErythropoietin receptorNucleotide
Owner:GENODYSSEE SA
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
InactiveUS9229010B2Peptide/protein ingredientsMammal material medical ingredientsFactor VIII vWFErythropoietin receptor
Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransfenin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.
Owner:ASTUTE MEDICAL
Preventives/remedies for thickened scar, keloid or chronic arthritic diseases
InactiveUS20040096447A1Good control effectImproving effect on progressive proliferation of collagen fibersPeptide/protein ingredientsAntipyreticErythropoietin AntibodyThickened scars
A pharmaceutical preparation for preventing and / or treating hypertrophic scars, keloid or chronic arthritic diseases comprising as an effective component an erythropoietin antagonist. More specifically, there is provided a pharmaceutical preparation for preventing and / or treating hypertrophic scars, keloid or chronic arthritic diseases comprising as an effective component an erythropoietin antagonist such as an anti-erythropoietin antibody, an erythropoietin receptor protein, etc. This pharmaceutical preparation has excellent prophylactic and / or therapeutic effects on collagenous hyperproliferation such as hypertrophic scars, keloid, etc., or chronic arthritic diseases such as rheumatoid arthritis, etc.
Owner:YASUDA YOSHIKO
Erythropoietin and erythropoietin receptor expression in human cancer
InactiveUS20050260580A1Inhibit cell proliferationPeptide/protein ingredientsMicrobiological testing/measurementHuman cancerErythropoietin receptor
The present invention relates to the elucidation of the role of erythropoietin and the erythropoietin receptor in the development and progression of certain solid tumors, including those found in breast, cervical, uterine, ovarian, prostate and brain cancer.
Owner:THE HENRY M JACKSON FOUND FOR THE ADVANCEMENT OF MILITARY MEDICINE INC
Preventives/remedies for thickened scar, keloid or chronic arthritic diseases
InactiveUS7300916B2Good control effectImproving effect on progressive proliferation of collagen fibersPeptide/protein ingredientsAntipyreticErythropoietin AntibodyErythropoietin receptor
A pharmaceutical preparation for preventing and / or treating hypertrophic scars, keloid or chronic arthritic diseases comprising as an effective component an erythropoietin antagonist. More specifically, there is provided a pharmaceutical preparation for preventing and / or treating hypertrophic scars, keloid or chronic arthritic diseases comprising as an effective component an erythropoietin antagonist such as an anti-erythropoietin antibody, an erythropoietin receptor protein, etc. This pharmaceutical preparation has excellent prophylactic and / or therapeutic effects on collagenous hyperproliferation such as hypertrophic scars, keloid, etc., or chronic arthritic diseases such as rheumatoid arthritis, etc.
Owner:YASUDA YOSHIKO
Affinity small molecules for the EPO receptor
Owner:F HOFFMANN LA ROCHE INC
Novel Feline Erythropoietin Receptor Agonists
InactiveUS20160083444A1Long serum half lifeIncrease contentPeptide/protein ingredientsAntibody mimetics/scaffoldsErythropoietin receptorAgonist
The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.
Owner:ASKGENE PHARM INC
Medicaments
A drug conjugate comprising a targeting agent and an anti-cancer agent, wherein said targeting agent comprises an erythropoietin receptor ligand, is described. The drug conjugate can be used in methods of treating cancer. Also described are methods of treating cancer using the conjugate, methods of diagnosis, methods of imaging and pharmaceutical compositions.
Owner:QUEENS UNIV OF BELFAST
Affinity small molecules for the EPO receptor
Compounds are provided that complex with the modulating domain of erythropoietin receptor (EPO-R) for use with EPO-R to determine the presence of EPO-R, the ability of other molecules to bind to the modulating domain in competitive assays and to induce a signal by EPO-R into a cell when bound by the subject compounds in a physiological environment. The compounds are characterized by having a six-membered heterocyclic ring comprising at least one nitrogen atom and include substituted triazolopyrimidine, pyridazinone, pyridine and piperidine.
Owner:F HOFFMANN LA ROCHE & CO AG
New compounds as positive allosteric modulators for erythropoietin and erythropoietin receptor to treat erythropoietin deficiency diseases
ActiveUS20170027970A1Organic active ingredientsSenses disorderErythropoietin receptorAllosteric modulator
Disclosed are compounds which can act as a positive allosteric modulator for erythropoietin and erythropoietin receptor and have the activity in promoting erythropoiesis. Also disclosed are pharmaceutical compositions comprising said compounds and treatment methods utilizing said compounds.
Owner:NATIONAL YANG MING UNIVERSITY
Preventives/remedies for proliferative organ diseases chronic arthritic diseases. hypertrophic scar or keloid
InactiveUS20040266676A1Low toxicityImprove operational capabilitiesOrganic active ingredientsPeptide/protein ingredientsErythropoietin receptorKeloid
An agent for prophylaxis or treatment of proliferative organ diseases, chronic arthritic diseases, hypertrophic scars or keloid, comprising an erythropoietin receptor antagonist or a salt thereof.
Owner:YASUDA
Use of erythropoietin and substances increasing and/or prolonging the activation and/or stimulation of erythropoietin receptors for treating and/or preventing schizophrenia and related psychoses
Owner:EHRENREICH HANNELORE
Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival
Owner:STATEGICS
Feline erythropoietin receptor agonists
InactiveUS10287336B2Long serum half lifeIncrease contentPeptide/protein ingredientsAntibody mimetics/scaffoldsErythropoietin receptorAgonist
Owner:ASKGENE PHARM INC
Preventives/remedies for proliferative organ diseases chronic arthritic diseases, hypertrophic scar or keloid
InactiveUS7053050B2Organic active ingredientsPeptide/protein ingredientsErythropoietin receptorKeloid
Owner:YASUDA
Erythropoietin and erythropoietin receptor expression in human cancer
InactiveUS7432051B2Peptide/protein ingredientsMicrobiological testing/measurementHuman cancerErythropoietin receptor
The present invention relates to the elucidation of the role of erythropoietin and the erythropoietin receptor in the development and progression of certain solid tumors, including those found in breast, cervical, uterine, ovarian, prostate and brain cancer.
Owner:THE HENRY M JACKSON FOUND FOR THE ADVANCEMENT OF MILITARY MEDICINE INC
Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
Methods and compositions are provided for protecting or enhancing the function or viability of effector cells, tissues, organs or body parts in mammals, including humans, in vivo, in situ or ex vivo, i.e. by systemic or local administration of recombinant tissue protective cells Factors such as modulators of erythropoietin receptor activity.
Owner:THE KENNETH S WARREN INST +1
Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
Owner:STATEGICS
Rat's IL-17RE span film region and cell inner region poly peptide and coding sequence, fusion protein and clone
The invention discloses white rat IL-17RE membrane crossing area and inside cell area polypeptide and the coding sequence, fusion albumen and cell line. The polypeptide is one sequence of the following aminoacid residue: SEQ ID No:2, the albumen relative to cell transferring of SEQ ID No:1 that has been replaced and / or lacking and / or adding one to ten aminoacid residue and passing RAS / MAPK signal channel path to take mitosis. Interfusing albumen of the polypeptide and the out area of the rat resource erythropoietin has one sequence of the following aminoacid residue: SEQ ID No:2, the albumen relative to cell transferring of SEQ ID No:1 that has been replaced and / or lacking and / or adding one to ten aminoacid residue and passing RAS / MAPK signal channel path to take mitosis. It has great actual value and wide application prospect.
Owner:TSINGHUA UNIV
Compounds as positive allosteric modulators for erythropoietin and erythropoietin receptor to treat erythropoietin deficiency diseases
Disclosed are compounds which can act as a positive allosteric modulator for erythropoietin and erythropoietin receptor and have the activity in promoting erythropoiesis. Also disclosed are pharmaceutical compositions comprising said compounds and treatment methods utilizing said compounds.
Owner:NATIONAL YANG MING UNIVERSITY
Compositions comprising antisense-encoded erythropoietin receptor and use thereof
ActiveUS20190262376A1Organic active ingredientsMicroencapsulation basedErythropoietin receptorNanoparticle
Provided herein are nanoparticles comprising antisense-encoded erythropoietin receptor (RopE) alone or in combination with erythropoietin receptor (EpoR). Also provided herein are methods of treating or preventing lungs disorders comprising administering RopE alone or in combination with EpoR.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Substituted amino acids as erythropoietin mimetics
InactiveUS7153869B2Easy to managePotential for oral activityBiocidePeptide/protein ingredientsErythropoietin receptorReceptor for activated C kinase 1
Owner:ORTHO MCNEIL PHARM INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com